Kane Biotech 

$0.02
2
+$0+0% Monday 14:54

Statistics

Day High
0.02
Day Low
0.02
52W High
0.07
52W Low
0.02
Volume
50,000
Avg. Volume
16,575
Mkt Cap
3.68M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

24NovExpected
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-0.01
-0.01
-0.01
-0.01
Expected EPS
N/A
Actual EPS
-0.0064

Financials

-489.98%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
312,881.45Revenue
-1.53MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KNBIF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. develops and produces medicines and vaccines for a wide range of medical disciplines, including biotherapeutics for wound healing, which competes with Kane Biotech's biofilm products.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson engages in the research and development of biopharmaceutical products, directly competing in the wound care market where Kane Biotech is also active.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories operates in the healthcare sector focusing on medical devices, diagnostics, and nutritional products that overlap with Kane Biotech's therapeutic areas.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. provides healthcare solutions including anti-infective agents and wound care treatments that compete with Kane Biotech's antimicrobial technologies.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. focuses on human therapeutics, including treatments in inflammation that compete with Kane Biotech's anti-biofilm products used in various medical applications.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. develops and markets drugs in areas such as infectious disease, which competes with Kane Biotech's focus on biofilm-preventive healthcare solutions.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is involved in biopharmaceutical products targeting inflammatory conditions, directly competing with Kane's biofilm technology in medical treatments.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb Company offers biopharmaceutical products, including those for wound healing and infection prevention, areas where Kane Biotech also operates.
Novartis
NVS
Mkt Cap237.61B
Novartis AG focuses on innovative healthcare solutions including advanced wound care, competing in the same space as Kane Biotech's biofilm-targeting products.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company develops pharmaceutical products that address chronic conditions, overlapping with Kane Biotech's focus on chronic wound infections and care.

About

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.
Show more...
CEO
Dr. Robert B. Huizinga CNeph(C), M.Sc., MSc(Epi), Ph.D., R.N., RN NNC
Country
US
ISIN
CA4838092084

Listings

0 Comments

Share your thoughts

FAQ

What is Kane Biotech stock price today?
The current price of KNBIF is $0.02 USD — it has increased by +0% in the past 24 hours. Watch Kane Biotech stock price performance more closely on the chart.
What is Kane Biotech stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kane Biotech stocks are traded under the ticker KNBIF.
Is Kane Biotech stock price growing?
KNBIF stock has risen by +0.46% compared to the previous week, the month change is a +4.76% rise, over the last year Kane Biotech has showed a -68.66% decrease.
What is Kane Biotech market cap?
Today Kane Biotech has the market capitalization of 3.68M
What were Kane Biotech earnings last quarter?
KNBIF earnings for the last quarter are -0.01 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Kane Biotech revenue for the last year?
Kane Biotech revenue for the last year amounts to 312,881.45 USD.
What is Kane Biotech net income for the last year?
KNBIF net income for the last year is -1.53M USD.
In which sector is Kane Biotech located?
Kane Biotech operates in the Health Care sector.
When did Kane Biotech complete a stock split?
The last stock split for Kane Biotech was on March 13, 2017 with a ratio of 1:5.
Where is Kane Biotech headquartered?
Kane Biotech is headquartered in Winnipeg, US.